David Farabee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Farabee has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
Sheldon Zhang
University of Massachusetts Lowell, USA
11 shared publications- Adeline Nyamathi
University of California, Los Angeles, CA, USA
10 shared publications Benissa E. Salem
School of Nursing, University of California–Los Angeles, Los Angeles, California, USA
7 shared publicationsFarinaz Khalilifard
Adeline Nyamathi, ANP, PhD, FAAN, is Distinguished Professor; and Benissa E. Salem, RN, MSN, PhD, is Adjunct Assistant Professor, School of Nursing, University of California, Los Angeles
7 shared publicationsMark Faucette
Adeline M. Nyamathi, ANP, PhD, FAAN, is Distinguished Professor, School of Nursing, University of California at Los Angeles
7 shared publicationsBarbara Leake
Adeline Nyamathi, ANP, PhD, FAAN, is Distinguished Professor; and Benissa E. Salem, RN, MSN, PhD, is Adjunct Assistant Professor, School of Nursing, University of California, Los Angeles
6 shared publications
Latest Publications
- Open Access
- 27 October 2025
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 20 (1) , 1-8
A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail
Context/background: The high prevalence of opioid use among jailed adults offers an unmatched opportunity to identify and treat those with opioid use disorder (OUD), a population that is at a substantial risk for post-release overdose. From a public health perspective, jails are critical touchpoints, as these facilities typically admit more than 7 million adults per year. One clinical consideration is whether pre-trial detainees with OUD would benefit from early induction onto extended-release buprenorphine (XRB). Methods/study design: In this 3-year randomized controlled trial, we will identify and recruit 200 incarcerated adults with OUD who are receiving sublingual buprenorphine (SLB) or tolerate a SLB test dose and randomize them to receive extended release buprenorphine (XRB) ( n = 100) or to remain on SLB ( n = 100) while in custody. Study participation will continue through their pre-trial time in jail (up to 6 months) or until they are sentenced or released. Community treatment will then be tracked for 90 days following release. In addition to collecting data on XRB uptake in jail, we will assess (1) the percentage of XRB and SLB study participants leaving jail with a clinically active dose of buprenorphine in their system, (2) 90- day post-release MOUD continuation, (3) levels of buprenorphine diversion while in custody, and (4) recidivism and death (90 days). “Clinically active” is defined as receiving XRB within the past 28 days or SLB in the past 24 h. Discussion: Findings from this study will demonstrate the feasibility and outcomes of inducting pre-trial adults with OUD onto XRB, as well as offer practical clinical and policy guidelines for best practices for treating this high risk and understudied population.
- 27 October 2025
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 20 (1) , 1-8
Open AccessA protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail
Context/background: The high prevalence of opioid use among jailed adults offers an unmatched opportunity to identify and treat those with opioid use disorder (OUD), a population that is at a substantial risk for post-release overdose. From a public health perspective, jails are critical touchpoints, as these facilities typically admit more than 7 million adults per year. One clinical consideration is whether pre-trial detainees with OUD would benefit from early induction onto extended-release buprenorphine (XRB). Methods/study design: In this 3-year randomized controlled trial, we will identify and recruit 200 incarcerated adults with OUD who are receiving sublingual buprenorphine (SLB) or tolerate a SLB test dose and randomize them to receive extended release buprenorphine (XRB) ( n = 100) or to remain on SLB ( n = 100) while in custody. Study participation will continue through their pre-trial time in jail (up to 6 months) or until they are sentenced or released. Community treatment will then be tracked for 90 days following release. In addition to collecting data on XRB uptake in jail, we will assess (1) the percentage of XRB and SLB study participants leaving jail with a clinically active dose of buprenorphine in their system, (2) 90- day post-release MOUD continuation, (3) levels of buprenorphine diversion while in custody, and (4) recidivism and death (90 days). “Clinically active” is defined as receiving XRB within the past 28 days or SLB in the past 24 h. Discussion: Findings from this study will demonstrate the feasibility and outcomes of inducting pre-trial adults with OUD onto XRB, as well as offer practical clinical and policy guidelines for best practices for treating this high risk and understudied population.
- 13 November 2024
- Published by Springer Nature in Community Mental Health Journal
- Vol. 61 (4) , 704-715
Exploring Reentry Concerns of Incarcerated Individuals with Severe Mental Illness
Little is known about the factors and circumstances that relate to how incarcerated individuals with serious mental illness (SMI) view their own needs upon reentry and their ability to meet them. In this study, 101 imprisoned adults with SMI rated their level of concern over meeting their basic needs and obtaining services following incarceration. Greater reentry concern was predicted by anticipated barriers to psychological care and increased psychological distress. When participants were asked what factors concerned them most, 51% identified housing, 41% financial concerns, and 39% obtaining services. The extent level of concern related to recidivism (rearrest during the 6-month follow-up post-release) was also examined; no significant relationship was observed. Findings align with prior research, suggesting that there should be less emphasis on convincing individuals of the value of mental health care and a greater focus on how to help them meet other demands that may prevent them from seeking such services.
- 13 November 2024
- Published by Springer Nature in Community Mental Health Journal
- Vol. 61 (4) , 704-715
Exploring Reentry Concerns of Incarcerated Individuals with Severe Mental Illness
Little is known about the factors and circumstances that relate to how incarcerated individuals with serious mental illness (SMI) view their own needs upon reentry and their ability to meet them. In this study, 101 imprisoned adults with SMI rated their level of concern over meeting their basic needs and obtaining services following incarceration. Greater reentry concern was predicted by anticipated barriers to psychological care and increased psychological distress. When participants were asked what factors concerned them most, 51% identified housing, 41% financial concerns, and 39% obtaining services. The extent level of concern related to recidivism (rearrest during the 6-month follow-up post-release) was also examined; no significant relationship was observed. Findings align with prior research, suggesting that there should be less emphasis on convincing individuals of the value of mental health care and a greater focus on how to help them meet other demands that may prevent them from seeking such services.
- Open Access
- 6 July 2023
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 45 (4) , 930-934
Perceptions of COVID-19 vaccine side effects by political affiliation
We sought to assess the extent to which subjective experiences of COVID-19 vaccine side effects among US adults are associated with political party identification. An online survey was conducted of a national sample of US adults (N = 1259) identifying as either Republican or Democrat. There was no significant difference by party identification in the perceived severity of vaccination side effects; however, Republicans were significantly less likely to recommend the vaccine to others in light of their experience (OR = 0.40; 95% CI, 0.31–0.51; P < 0.001). Republicans also reported having a larger share of COVID-19-vaccinated friends and family who experienced notable side effects (OR = 1.31; 95% CI, 1.02–1.68; P < 0.05). There was a positive association between respondents’ perceived side-effect severity and the proportion of peers who also reported notable side effects (r = 0.43; P < 0.001). Subjective appraisals of the vaccinated may affect broader vaccine acceptability.
- 6 July 2023
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 45 (4) , 930-934
Open AccessPerceptions of COVID-19 vaccine side effects by political affiliation
We sought to assess the extent to which subjective experiences of COVID-19 vaccine side effects among US adults are associated with political party identification. An online survey was conducted of a national sample of US adults (N = 1259) identifying as either Republican or Democrat. There was no significant difference by party identification in the perceived severity of vaccination side effects; however, Republicans were significantly less likely to recommend the vaccine to others in light of their experience (OR = 0.40; 95% CI, 0.31–0.51; P < 0.001). Republicans also reported having a larger share of COVID-19-vaccinated friends and family who experienced notable side effects (OR = 1.31; 95% CI, 1.02–1.68; P < 0.05). There was a positive association between respondents’ perceived side-effect severity and the proportion of peers who also reported notable side effects (r = 0.43; P < 0.001). Subjective appraisals of the vaccinated may affect broader vaccine acceptability.
- 29 July 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (6) , 389-397
Substance Use, Mental Health, and Child Welfare Profiles of Juvenile Justice-Involved Commercially Sexually Exploited Youth
Objectives: To describe the substance use profiles of youth impacted by commercial sexual exploitation (CSE) and explore associations between substance use with mental health diagnoses and child welfare involvement. Methods: Data were systematically extracted from the court files of 364 youth who participated between 2012 and 2016 in Los Angeles County's Succeeding Through Achievement and Resilience (STAR) Court, a juvenile delinquency specialty court for youth impacted by CSE. Descriptive statistics and multivariate regression analyses were conducted to quantify associations between youths' substance use with mental health diagnoses and child welfare involvement. Results: Of the 364 youth impacted by CSE involved in the STAR Court, 265 youth had documented contact with a psychiatrist while in court—of whom, 73% were diagnosed with at least one mental health challenge. Before STAR Court participation, 74% of youth were the subject of one or more child welfare referral; of these youth, 75% had prior out-of-home care. Eighty-eight percent of youth reported substance use, the most prevalent illicit substances were marijuana (87%), alcohol (54%), and methamphetamine (33%). Controlling for age and race, youth impacted by CSE with a diagnosed general mood disorder had more than five times the odds of reporting substance use compared with those without a mood disorder diagnosis (adjusted odds ratio [AOR]: 5.80; 95% confidence interval CI: 2.22–18.52; p < 0.001); and youth impacted by CSE with prior child welfare placements had more than two times the odds of reporting substance use (AOR: 2.24; 95% CI: 1.04–4.86; p = 0.039) compared with youth without prior placements. The association between substance use and general mood disorder was significant and positive for all substance use types (AOR = 3.3, p = 0.033 marijuana; AOR = 4.01, p = 0.011 concurrent alcohol and marijuana; AOR = 9.2, p < 0.001, polysubstance use). Conclusions: High prevalence of substance use among juvenile justice-involved youth impacted by CSE combined with strong associations between substance use with both mental health diagnoses and child welfare system history underscores the need for comprehensive, specialized substance use treatment. Findings suggest an important opportunity for multidisciplinary collaboration among mental health providers, child welfare professionals, juvenile justice practitioners, and other care providers for these youth.
- 29 July 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (6) , 389-397
Substance Use, Mental Health, and Child Welfare Profiles of Juvenile Justice-Involved Commercially Sexually Exploited Youth
Objectives: To describe the substance use profiles of youth impacted by commercial sexual exploitation (CSE) and explore associations between substance use with mental health diagnoses and child welfare involvement. Methods: Data were systematically extracted from the court files of 364 youth who participated between 2012 and 2016 in Los Angeles County's Succeeding Through Achievement and Resilience (STAR) Court, a juvenile delinquency specialty court for youth impacted by CSE. Descriptive statistics and multivariate regression analyses were conducted to quantify associations between youths' substance use with mental health diagnoses and child welfare involvement. Results: Of the 364 youth impacted by CSE involved in the STAR Court, 265 youth had documented contact with a psychiatrist while in court—of whom, 73% were diagnosed with at least one mental health challenge. Before STAR Court participation, 74% of youth were the subject of one or more child welfare referral; of these youth, 75% had prior out-of-home care. Eighty-eight percent of youth reported substance use, the most prevalent illicit substances were marijuana (87%), alcohol (54%), and methamphetamine (33%). Controlling for age and race, youth impacted by CSE with a diagnosed general mood disorder had more than five times the odds of reporting substance use compared with those without a mood disorder diagnosis (adjusted odds ratio [AOR]: 5.80; 95% confidence interval CI: 2.22–18.52; p < 0.001); and youth impacted by CSE with prior child welfare placements had more than two times the odds of reporting substance use (AOR: 2.24; 95% CI: 1.04–4.86; p = 0.039) compared with youth without prior placements. The association between substance use and general mood disorder was significant and positive for all substance use types (AOR = 3.3, p = 0.033 marijuana; AOR = 4.01, p = 0.011 concurrent alcohol and marijuana; AOR = 9.2, p < 0.001, polysubstance use). Conclusions: High prevalence of substance use among juvenile justice-involved youth impacted by CSE combined with strong associations between substance use with both mental health diagnoses and child welfare system history underscores the need for comprehensive, specialized substance use treatment. Findings suggest an important opportunity for multidisciplinary collaboration among mental health providers, child welfare professionals, juvenile justice practitioners, and other care providers for these youth.
- Open Access
- 1 February 2020
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 11, 21-22
An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]
An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]
- 1 February 2020
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 11, 21-22
Open AccessAn Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]
An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]
- 1 February 2020
- Published by Elsevier in Child Abuse & Neglect
- Vol. 100, 104041
A specialty court for U.S. youth impacted by commercial sexual exploitation
- 1 February 2020
- Published by Elsevier in Child Abuse & Neglect
- Vol. 100, 104041
A specialty court for U.S. youth impacted by commercial sexual exploitation
- Open Access
- 1 June 2019
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 10, 13-21
Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
Purpose: The Treatment Effectiveness Assessment (TEA) is a patient-centered instrument for evaluating treatment progress and recovery from substance use disorders, including opioid use disorder (OUD). We assessed the TEA’s reliability and validity and determined minimal clinically important differences (MIDs) in participants with moderate to severe OUD. Patients and methods: The TEA measures change in four single-item domains (substance use, health, lifestyle, community involvement) from treatment initiation across the duration of a treatment program. Self-reported responses range from 1 (“none or not much”) to 10 (“much better”) with items summed to a total score ranging from 4–40. We assessed floor and ceiling effects, internal consistency, test-retest reliability, known-groups validity (ANOVA stratified by current health status [36-Item Short Form Health Survey item 1]), convergent/divergent validity, and MIDs using data from a phase 3, open-label clinical trial of buprenorphine extended-release monthly injection for subcutaneous use (BUP-XR). Participants with OUD completed the TEA at screening and before monthly injections for up to 12 months. Results: Among 410 participants (mean age 38 years; 64% male), the mean baseline (pre-injection 1) TEA total score was 25.4 (SD 9.7), with PConclusion: The TEA exhibited acceptable reliability and validity in a cohort of participants with moderate to severe OUD treated with BUP-XR. Given its brevity and psychometric properties, the TEA is a promising tool for use in clinical practice and research.
- 1 June 2019
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 10, 13-21
Open AccessMeasuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
Purpose: The Treatment Effectiveness Assessment (TEA) is a patient-centered instrument for evaluating treatment progress and recovery from substance use disorders, including opioid use disorder (OUD). We assessed the TEA’s reliability and validity and determined minimal clinically important differences (MIDs) in participants with moderate to severe OUD. Patients and methods: The TEA measures change in four single-item domains (substance use, health, lifestyle, community involvement) from treatment initiation across the duration of a treatment program. Self-reported responses range from 1 (“none or not much”) to 10 (“much better”) with items summed to a total score ranging from 4–40. We assessed floor and ceiling effects, internal consistency, test-retest reliability, known-groups validity (ANOVA stratified by current health status [36-Item Short Form Health Survey item 1]), convergent/divergent validity, and MIDs using data from a phase 3, open-label clinical trial of buprenorphine extended-release monthly injection for subcutaneous use (BUP-XR). Participants with OUD completed the TEA at screening and before monthly injections for up to 12 months. Results: Among 410 participants (mean age 38 years; 64% male), the mean baseline (pre-injection 1) TEA total score was 25.4 (SD 9.7), with PConclusion: The TEA exhibited acceptable reliability and validity in a cohort of participants with moderate to severe OUD treated with BUP-XR. Given its brevity and psychometric properties, the TEA is a promising tool for use in clinical practice and research.